According to a document disclosed by the U.S. Securities and Exchange Commission (SEC) on April 21, 2026, Aaron Wealth Advisors LLC purchased 1,098,176 shares of MBX Biosciences (MBX) in the first quarter. Based on the estimated average closing price for the quarter, the transaction was valued at approximately $37.35 million. After accounting for net purchases and price changes, the value of this position increased by $32.66 million by the end of the quarter.
This was an increase in holdings. Following the filing, the MBX Biosciences position represented 1.98% of Aaron Wealth Advisors LLC’s reportable 13F asset portfolio.
As of April 20, 2026, MBX Biosciences’ stock closed at $33.78, with a gain of 342.1% over the past year. In terms of price movement, it outperformed the S&P 500 by 308.73 percentage points. The company has a market capitalization of approximately $1.61 billion and reported a net loss of $86.97 million over the trailing twelve months.
MBX Biosciences is a clinical-stage biotechnology company focused on developing precision peptide therapies for endocrine and metabolic disorders. Its pipeline includes: MBX 2109, currently in Phase 2 clinical trials for chronic hypoparathyroidism; MBX 1416, in Phase 1 clinical trials for post-bariatric hypoglycemia; and MBX 4291, in preclinical development for obesity and related comorbidities. The company is committed to addressing unmet medical needs in orphan and specialty disease markets through proprietary discovery, development, and potential future commercialization or licensing, with a strategic emphasis on differentiated long-acting therapies.
For investors, Aaron Wealth Advisors expanded its MBX Biosciences position from 70,000 shares at the end of 2025 to 1,168,176 shares in the first quarter of 2026. However, for this fund, the stock has risen only about 7% so far this year. The institution appears bullish on MBX Biosciences’ lead candidate, canvuparatide. In March, MBX Biosciences informed investors that the U.S. Food and Drug Administration (FDA) had provided feedback supporting the company’s planned Phase 3 clinical trial. MBX Biosciences plans to initiate a Phase 3 study of canvuparatide in the third quarter. This parathyroid hormone peptide prodrug is designed as a long-acting replacement therapy for patients with hypoparathyroidism. In September of last year, MBX Biosciences announced positive Phase 2 results for canvuparatide: once-weekly subcutaneous injections significantly improved patients’ ability to maintain normal blood calcium levels without relying on conventional therapy. The company plans to enroll approximately 160 patients for 26 weeks of treatment and observation. Achieving normal blood calcium levels and discontinuing conventional therapy will be the primary endpoint of this pivotal trial.
